Oppenheimer Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Oppenheimer Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-38,191	Closed	-$4.35M	–	1200
2022 Q4	$4.35M	Sell	38,191 -700	-2%	-$58.1K	0.07%	292
2022 Q3	$2.41M	Sell	38,891 -1,084	-3%	-$75.7K	0.04%	408
2022 Q2	$3.19M	Sell	39,975 -1,785	-4%	-$169K	0.05%	352
2022 Q1	$4.39M	Sell	41,760 -1,308	-3%	-$127K	0.06%	319
2021 Q4	$4.64M	Sell	43,068 -676	-2%	-$73.7K	0.06%	322
2021 Q3	$4.79M	Sell	43,744 -573	-1%	-$59.5K	0.07%	307
2021 Q2	$4.15M	Sell	44,317 -1,160	-3%	-$107K	0.06%	337
2021 Q1	$4.19M	Buy	45,477 +8,225	+22%	+$694K	0.06%	322
2020 Q4	$2.73M	Buy	37,252 +8,197	+28%	+$609K	0.05%	397
2020 Q3	$2.26M	Sell	29,055 -508	-2%	-$35K	0.04%	404
2020 Q2	$1.64M	Buy	+29,563	New	+$1.26M	0.03%	449
2017 Q3	–	Sell	-12,608	Closed	-$150K	–	1735
2017 Q2	$150K	Sell	12,608 -8,843	-41%	-$110K	﹤0.01%	1101
2017 Q1	$317K	Buy	+21,451	New	+$347K	0.01%	908

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oppenheimer Asset Management's HZNP Position: Q1 2023 in Review

Oppenheimer Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 38,191 shares — an estimated $4.35M sold.

Oppenheimer Asset Management first reported a position in HZNP in Q1 2017 and held it in 13 quarters. The position peaked at $4.79M in Q3 2021. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Oppenheimer Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Oppenheimer Asset Management sold 38,191 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $4.35M.
Oppenheimer Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017 and held it in 13 quarters.
Oppenheimer Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.79M in Q3 2021.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Oppenheimer Asset Management's 13F filing for Q1 2023, filed 10 May 2023.